Biologics for Rheumatoid Arthritis: How They Work and What to Expect

Biologics for Rheumatoid Arthritis

Biologic medications have revolutionized rheumatoid arthritis (RA) treatment over the past 25 years. For patients who don't respond adequately to traditional disease-modifying antirheumatic drugs (DMARDs) like methotrexate, biologics offer targeted, highly effective therapy.

What Are Biologics?

Biologics are protein-based medications derived from living cells. Unlike traditional DMARDs that broadly suppress the immune system, biologics target specific molecules involved in the inflammatory process that drives RA.

Classes of Biologics for RA

1. TNF Inhibitors (most commonly used)

Block tumor necrosis factor (TNF), a key inflammatory cytokine.

• Etanercept (Enbrel)
• Adalimumab (Humira)
• Infliximab (Remicade)
• Certolizumab pegol (Cimzia)
• Golimumab (Simponi)

2. IL-6 Receptor Inhibitors

Block interleukin-6, another key inflammatory driver.

• Tocilizumab (Actemra)
• Sarilumab (Kevzara)

3. B-Cell Depleting Agents

Target CD20 on B cells, reducing antibody production.

• Rituximab (Rituxan)

4. T-Cell Costimulation Inhibitors

Prevent T-cell activation.

• Abatacept (Orencia)

5. JAK Inhibitors (targeted synthetic DMARDs)

Block Janus kinase enzymes involved in inflammation signaling.

• Tofacitinib (Xeljanz)
• Baricitinib (Olumiant)
• Upadacitinib (Rinvoq)

How Effective Are Biologics?

For patients who have failed methotrexate, biologics achieve:

• ACR20 response (20% improvement): 50-70% of patients
• ACR50 response (50% improvement): 30-50% of patients
• Remission: 20-40% of patients

TNF inhibitors are typically tried first. If one fails, switching to a different TNF inhibitor or a different class often works.

Safety Considerations

Infection risk: Biologics suppress parts of the immune system, increasing infection risk — particularly tuberculosis (TB), fungal infections, and bacterial infections.

• TB screening required before starting most biologics
• Avoid live vaccines while on biologics
• Report fever, chills, or unusual infections promptly

Malignancy: Slightly increased risk of certain cancers (lymphoma, skin cancer) with long-term use, though the absolute risk increase is small.

Cardiovascular: JAK inhibitors carry FDA black box warnings for increased risk of heart attack, stroke, and blood clots, particularly in patients over 50 with cardiovascular risk factors.

Biosimilars

Biosimilars are FDA-approved versions of biologics with the same clinical effect at significantly lower cost. Multiple biosimilars are available for adalimumab, etanercept, and infliximab.

Medical Disclaimer

Biologic therapy for RA requires careful monitoring by a rheumatologist. Do not start, stop, or change biologic medications without medical supervision.